Suppressing obesity and over-secretion of insulin with
申请人:Takeda Chemical Industries, Ltd.
公开号:US04349547A1
公开(公告)日:1982-09-14
2-(.alpha.-hydroxy-m-trifluoromethylbenzyl)azetidine and its physiologically acceptable acid addition salts have antiobesity action as well as suppressive action against oversecretion of insulin.
[EN] 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS<br/>[FR] ENANTIOMERES 3-PYRIDYL ET LEUR UTILISATION COMME ANALGESIQUES
申请人:ABBOTT LABORATORIES
公开号:WO1998025920A1
公开(公告)日:1998-06-18
(EN) The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula (I) which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.(FR) La présente invention se rapporte à un procédé d'élimination de la douleur chez les mammifères et les êtres humains, ce procédé consistant à administrer à un mammifère ou à un être humain nécessitant ce traitement des composés sélectionnés de la formule (I) ou un sel pharmaceutiquement acceptable de ceux-ci. L'invention se rapporte également à des composés (R) et (S) sélectionnés de la formule (I) qui sont utilisés comme analgésiques et comme agents préventifs de la dégénérescense neuronale et comme anti-inflammatoires.
[EN] HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION<br/>[FR] COMPOSES ETHER ET THIOETHER HETEROCYCLIQUES UTILISES DANS LA REGULATION DE LA TRANSMISSION SYNAPTIQUE CHIMIQUE
申请人:ABBOTT LABORATORIES
公开号:WO1999032480A1
公开(公告)日:1999-07-01
(EN) Novel compounds having formulas (I), (II) or (III) or pharmaceutically-acceptable salts or prodrugs thereof, which are useful for controlling synaptic transmission; to therapeutically-effective pharmaceutical compositions of these compounds; and to the use of said compositions to controlling synaptic transmission in human or veterinary patients.(FR) L'invention porte sur de nouveaux composés ayant les formules (I), (II) ou (III), ou sur leurs sels pharmaceutiquement acceptables ou promédicaments, et qui sont utilisés dans la régulation de la transmission synaptique. L'invention porte également sur les compositions pharmaceutiques thérapeutiquement efficaces de ces composés, et sur l'utilisation de ces compositions pour réguler la transmission synaptique chez l'homme ou l'animal.
Process for producing optically active azetidine-2-carboxylic acids
申请人:Honda Tatsuya
公开号:US20050043547A1
公开(公告)日:2005-02-24
An optically active N-protected azetidine-2-carboxylic acid (5) can be produced by preparing an optically active 4-amino-2-halobutyric acid (3) by halogenating an optically active 3-hydroxy-2-pyrrolidinone (1) with inversion of configuration to prepare an optically active 3-halo-2-pyrrolidinone (2) followed by hydrolysis or by halogenating an optically active 4-amino-2-hydroxybutyric acid ester (6) with inversion of configuration to prepare an optically active 4-amino-2-halobutyric acid ester (7) followed by hydrolysis or by halogenating the compound. (6) with inversion of configuration to prepare the compound (7), cyclizing the same to prepare the compound (2) followed by hydrolysis,
further cyclizing the compound (3) followed by treating the reaction product with an amino group-protecting agent. The thus-obtained compound (5) can be improved its optical purity further by recrystallization.
Process for producing optically active azetidine-2-carboxylic acid
申请人:——
公开号:US20040171849A1
公开(公告)日:2004-09-02
The present invention provides an efficient, simple, and commercially advantageous process for producing optically active azetidine-2-carboxylic acid, which is an important material for medicines.
The process includes the steps of halogenating an optically active N-protected 4-amino-2-hydroxybutyric acid following inversion of the configuration to produce an optically active N-protected 4-amino-2-halobutyryl halide; hydrolyzing the halide; deprotecting the amino group of the hydrolyzed product to produce an optically active 4-amino-2-halobutyric acid; cyclizing the product in an alkaline aqueous solution; and then protecting the amino group of the cyclized product to produce an optically active N-protected azetidine-2-carboxylic acid.
The present invention also provides an optically active N-protected 4-amino-2-halobutyryl halide represented by general formula (2):
1
(wherein P represents a protective group for the primary amino group; * indicates that the carbon atom is asymmetric; and each of X and Y independently represents a halogen atom), which is useful for producing the optically active azetidine-2-carboxylic acid.